Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Should gemcitabine be used as adjuvant chemotherapy in patients with resectable pancreatic cancer?

Nature Clinical Practice Gastroenterology & Hepatology volume 4, pages 362–363 (2007)Cite this article

boxed-textOettle H et al. (2007) Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 297: 267–277

This is a preview of subscription content

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

Buy

All prices are NET prices.

References

  1. No authors listed (1987) Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Gastrointestinal Tumor Study Group. Cancer 59: 2006–2610

  2. Klinkenbijl JH et al. (1999) Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 230: 776–784

    CAS  Article  Google Scholar 

  3. Neoptolemos JP et al. (2004) A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 350: 1200–1210

    CAS  Article  Google Scholar 

  4. Regine WF et al. (2006) RTOG 9704 a phase III study of adjuvant pre and post chemoradiation (CRT) 5-FU vs. gemcitabine (G) for resected pancreatic adenocarcinoma. J Clin Oncol In ASCO Annual Meeting Proceedings Part I 24: A4007

    Google Scholar 

Download references

Acknowledgements

The synopsis was written by Rachel Jones, Associate Editor, Nature Clinical Practice.

Author information

Affiliations

  1. BH O'Neil is an Assistant Professor and RM Goldberg is Professor and Chief of the Division of Hematology and Oncology at the University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA.

    Bert H O'Neil & Richard M Goldberg

Authors
  1. Bert H O'Neil
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Richard M Goldberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bert H O'Neil.

Ethics declarations

Competing interests

RM Goldberg is a Consultant for Eli Lilly. B O'Neil declared he has no competing interests.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

O'Neil, B., Goldberg, R. Should gemcitabine be used as adjuvant chemotherapy in patients with resectable pancreatic cancer?. Nat Rev Gastroenterol Hepatol 4, 362–363 (2007). https://doi.org/10.1038/ncpgasthep0817

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpgasthep0817

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing